Sign in
Taking peoplePhase 1/2

Dual-targeting of B & T Cell Pathways Evaluation Trial

Key facts

Who runs it
Diabetes Free, Inc.
Where
Germany1 site in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 1/2
People taking part
72 people, planned
Starts
1 Dec 2026
Expected to end
Dec 2028
Type of study
Interventional, 2 groups
Treatments tested
  • DFI205 bispecific antibody
Record updated
18 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Male and female participants, age 18 years and older
  • Able to understand and comply with all scheduled visits, treatment plans, laboratory tests, and other procedures of the study protocol including ability to provide written informed consent
  • Maintaining a stable, qualifying, standard of care regimen for ≥4 weeks prior to screening as treatment for a qualifying primary diagnosis (RA, SLE, SSc, IIM including the disease-specific criteria listed below):
  • Rheumatoid Arthritis (RA) participants must have, 1) positivity of anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor (RF); 2) moderate to highly active disease despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months; secondary Sjögren's disease diagnosis is acceptable as long as other criteria are met
  • Systemic Lupus Erythematosus (SLE) participants must have, 1) positivity of anti-nuclear-antibodies (ANA) and/or anti-dsDNA and/or anti-histone and/or anti-nucleosome and/or anti-Sm antibodies; 2) active disease despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months
  • Systemic Sclerosis (SSc) participants must have, 1) positivity for at least one SSc-associated autoantibody; 2) mRSS score >10 units or interstitial lung disease (ILD) including clinically relevant pulmonary involvement despite treatment with at least 2 lines of standard therapy; 3) disease duration ≤ 5 years (from onset of first non-Raynaud manifestation); 4) not eligible for or declining autologous hematopoietic stem-cell transplantation
  • Idiopathic Inflammatory Myopathies (IIM) participants must have, 1) positivity for at least one myositis-specific antibody; 2) active myositis or presence of ILD defined by clinically relevant pulmonary involvement despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months

Who cannot take part

  • Acute infection requiring systemic therapy or hospitalization within 30 days before screening
  • Invasive aspergillus, histoplasmosis, or coccidioidomycosis infection within one year prior to enrollment
  • Systemic corticosteroid therapy or adrenocorticotropic hormone (ACTH) use within 30 days prior to screening and within entire duration of screening period prior to beginning of study treatment, unless prescribed as background therapy
  • Intolerance of or contraindication to oral or IV corticosteroids
  • Treatment with other biologic or non-biologic immunosuppressant agents (e.g., anti-CD20 therapies, TNF inhibitors, azathioprine, cyclosporine, methotrexate, or mycophenolate) within 6 months prior to screening, unless prescribed as background therapy
  • The participant has taken another investigational drug within 3 months or 5-half-lives before the screening visit, whichever is longer, or any investigational drug that has depleted a cell type or line without recovery
  • Previous treatment with anti-CD19 agents, anti-CD38 agents, bispecific anti-CD19/CD3 T cell engaging therapies, adoptive T cell therapy or any prior gene therapy product
  • Received any form of stem cell transplant
  • Administration of live attenuated vaccine(s) within 12 weeks prior to and 12 weeks after the completion of DFI205 administration or any planned receipt during the study that cannot be delayed. Vaccinations should be up-to-date as per local clinical practice
  • Plasmapheresis within 3 months prior to first dose of DFI205
  • Diagnosis of a non-rheumatic autoimmune disease requiring therapeutic or investigational immune therapy or modulation (e.g., neuropathy requiring IVIg, Multiple Sclerosis). Milder autoimmune conditions requiring replacement or exocrine functional therapies are acceptable (e.g., Type 1 diabetes, Celiac Disease, Autoimmune Thyroid Disease if on stable treatment for at least 6 months)
  • Severe unresolved cardiac disease
  • Any history of malignancy in the 5 years before screening except for completely resected squamous or basal cell carcinoma of the skin
  • History or evidence of progressive multifocal leukoencephalopathy (PML) or other demyelinating disorders
  • Allergies to humanized monoclonal antibodies or severe post-treatment hypersensitivity reactions other than localized injection site reaction, to any biological molecule
  • History of any pre-existing liver disease, including cirrhosis, acute liver disease, or chronic liver disease (unless considered stable for >6 months and required screening laboratory tests meet criteria)
  • Estimated glomerular filtration rate (GFR) <30 mL/min/1.73 m2
  • Presence or history of active infections, including hepatitis B, hepatitis C, human immunodeficiency virus (HIV), Human T-lymphotropic virus (HTLV) or tuberculosis. Participants with laboratory evidence of active infection are excluded even in the absence of clinical evidence of active infection. Participants with mild skin and nail fungal infections are not excluded
  • Any condition, including the presence of relevant abnormalities in vital parameters or laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  • Primary or secondary immunodeficiency, including hypogammaglobulinemia
  • Positive pregnancy test, presently breast-feeding, (female participants) or unwillingness to use highly effective contraceptive measures for the duration of the study and 6 months after discontinuation

This trial is currently available in Germany.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a first-in-human study of DFI205, an investigational bispecific antibody that binds CD20 and CD40, with the goal of targeting both B- and T-cell function in adults with active systemic autoimmune rheumatic diseases (SARDs) despite standard therapy. In Phase 1, participants with RA, SLE, SSc or IIM will receive a single dose at increasing dose levels to establish safety and initial treatment response. The selected dose will be carried forward into Phase 2a, where participants will receive monthly doses to assess safety and treatment response.

The 2 groups in the trial

  • Phase 1 Single Ascending Dose EscalationTreatment being tested

    Intravenous (IV) infusion of DFI205 at ascending dose levels.

    Treatment: DFI205 bispecific antibody

  • Phase 2a Multi-DoseTreatment being tested

    DFI205 monthly IV infusions at the recommended Phase 2 dose

    Treatment: DFI205 bispecific antibody

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Evaluation of Safety, Treatment Response and Biological Effects of DFI205 in Systemic Autoimmune Rheumatic Diseases (SARDs); a Phase 1/2a First-in-Human (FIH) Study
Record updated
18 November 2026